BY BRIELLE JAEKEL
United States citizens have always grappled with the idea of weight and beauty. For decades, countless trends have come and gone, shifting ideas of what the perfect body looks like from one year to the next. And its impact on health has not just manifested in physical effects, but has taken its toll on the mental health of our citizens, as well as our wallets.
Weight-loss trends in the U.S. have also suffered singularly focused capitalistic results, with many companies looking to jump on the latest “get skinny quick scheme.” But what cost has this had for the American individual?
For generations, Americans have heard that weight loss is a matter of discipline, willpower, and personal responsibility. The message has been repeated so often that it has hardened into a kind of cultural doctrine. Yet the lived reality is far more complicated. Nearly half of American adults have attempted to lose weight over the past three years, according to CDC-referenced reports, and the vast majority have tried more than once.
The cycle is familiar: the initial burst of motivation, the early victories, the inevitable plateau, the slow return of old habits, and the quiet disappointment that follows. Research suggests that only about five percent of individuals maintain their weight loss over time. The rest find themselves back where they started, or heavier than before, wondering what went wrong.
WILL HISTORY REPEAT ITSELF?
American culture has been through its fair share of weight-loss advice that would not age well, leaving generations to come disturbed at their descriptions after falling out of fashion.
Take, for instance, the tape worm craze of the early 20th century. Historical advertisements urged women to ingest pills containing tapeworm eggs, promising the ability to eat anything while remaining thin — an idea that completely horrifies Americans today.
Or how about the Master Cleanse, a liquid diet that requires participants to drink a beverage made of maple syrup, lemon juice, water, and cayenne pepper for 10 days. It was popularized in the early 2000s thanks to a book from Peter Glickman titled “Lose Weight, Have More Energy, and be Happier in 10 Days.” Beyonce even boasted on “The Oprah Winfrey Show” that she had lost 20 pounds thanks to the diet. While still referenced in detox and alternative wellness circles, the Master Cleanse and similar methods of liquid diets are not supported by clinical evidence and is widely regarded in medical literature as ineffective for detoxification or sustained weight loss (Mayo Clinic; Harvard T.H. Chan School of Public Health; NIH NCCIH).
The most prominent iterations of weight-loss trends have been various weight-loss drugs throughout the decades, ranging from Amphetamines in the 1940s and drug cocktails in the 1960s to Fen-Phen (short for phentermine) in the 1990s to herbal fat-burners containing Ephedra in the early 2000s.
Today, the expansion of data and information through the internet has created more opportunities for awareness of how dangerous and/or ineffective some of these methods are while also exploring many methods that could be highly beneficial, backed by scientific research.
WHERE WE STAND ON THE SCALES TODAY
We’ve maintained an obsession with body images, despite an increase in change of perspectives, like the emergence of body positive movements. However, the United States is still in the top 20 countries for obesity rates. It is considered the most obese country among all major high-income developed countries, according to the Organisation for Economic Co-operation and Development (OECD).
According to the Centers for Disease Control and Prevention (CDC), 42.8% of U.S. adults were considered obese as of 2018. With the growth of obesity in the United States and along with it, the surge of Type 2 Diabetes, doctors are now an integral part of weight loss.
The staggering statistics and dangerous health effects led to the introduction of the “Ozempic Diet.” Commercials for the drug started to appear staggered in between Americans’ content consumption, promising an easier life for those managing Type 2.
Ozempic was the prominent medication prescribed for obesity at the time, a glucagon-like peptide-1 that mimics a naturally occurring “incretin” gut hormone known as GLP-1.
Shortly after it started to become popular, a round of celebrities appeared in public, on television, and on social media, looking starkly different in appearance in what seemed like no time at all. The 2023 Academy Awards red carpet exploded with celebrities showing off jaw-dropping transformations, so much so that it was woven into the night’s jokes.
“Everybody looks so great,” Oscars’ host, Jimmy Kimmel, said in his opening monologue. “When I look around this room, I can’t help but wonder, ‘Is Ozempic right for me?'” nodding at a quote from the drug’s commercials.
While the drugs offered assistance to those who desperately needed it, they also offered a quick fix for those looking to lose weight fast.
The immense surge in demand, fueled by celebrity endorsement and social media, far outpaced manufacturing capacity. According to data from the FDA, individuals who did not meet the clinical criteria for severe obesity or type 2 diabetes were actively obtaining the medication, which triggered severe supply constraints for patients who relied on the drugs for chronic disease management.
Recognizing that the brand-name manufacturers could no longer meet national demand, the FDA officially placed critical GLP-1 medications on its national Drug Shortages list, including Wegovy, Ozempic and Mounjaro.
Since then, a range of similar drugs and compound versions have hit doctors’ offices and wellness boutiques alike. It’s definitely the noisiest weight-loss method currently, but it is not the only one. Since then, the FDA has removed GLP-1s from its shortage list.
And while these medications are certainly the buzzword of the decade for weight loss, they’re not the only weight loss treatments currently being used.
THE THREE PILLARS OF CONTEMPORARY OBESITY MEDICINE
Today, the most commonly prescribed treatments for obesity fall into three main categories, according to Dr. Fatima Cody Stanford, an obesity medicine physician educator and policy maker at Massachusetts General Hospital and Harvard Medical School.
“First, lifestyle-based interventions, including structured nutrition, physical activity, and behavioral therapy, remain foundational,” she explained. “Second, obesity management medications—particularly newer agents such as GLP-1 receptor agonists (such as semaglutide) and dual agonists (such as tirzepatide) — are now widely used due to their effectiveness.
“Other medications, including phentermine/topiramate, naltrexone/bupropion, and orlistat, are also prescribed, though generally with more modest results. Third, metabolic and bariatric surgery remains the most effective intervention for severe obesity and is underutilized relative to its benefits.”
Harvard medical experts emphasize that while all three major weight management strategies target the same end goal, they function through completely distinct biological pathways and yield varying degrees of success. Traditional behavioral and lifestyle modifications focus on maintaining a long-term calorie deficit to boost metabolic health; however, their success is often blunted by the body’s natural defense mechanisms, which adapt to resist weight loss.
In contrast, pharmacological treatments tackle obesity by directly intervening in these biological roadblocks. Modern GLP-1 therapies suppress overall caloric intake by interacting with the brain’s appetite-regulation centers — effectively dampening hunger signals, enhancing the sensation of fullness, and delaying gastric emptying. Advanced treatments like tirzepatide amplify this response by simultaneously activating both the GLP-1 and GIP pathways. At the same time, older weight-loss medications rely on less targeted methods, such as general central nervous system stimulation or blocking fat absorption in the digestive tract.
Ultimately, metabolic and bariatric surgery remains the most potent and long-lasting intervention. Rather than relying solely on physical restriction, surgery fundamentally rewires the body’s hormonal environment, alters complex gut signaling networks, and maintains continuous appetite suppression to deliver the most significant, durable results.
The rapid rise of GLP-1 medications has triggered an unprecedented contraction in the field of weight-loss surgery, reversing years of steady volume growth.
According to nationwide data presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Scientific Meeting, the total number of metabolic and bariatric procedures performed in the United States fell more than 20% between 2022 and 2024, hitting below the 200,000 threshold for the first time this decade. Another study published in JAMA Surgery by researchers at the Harvard T.H. Chan School of Public Health confirmed this acceleration, tracking an overall 34.1% decline in bariatric surgeries between 2022 and 2024 alongside a massive 140.4% surge in GLP-1 prescriptions.
Public health experts analyzing electronic health records from the multi-center Epic Cosmos database note that this decline is uniquely concentrated among patients with the highest degrees of severe obesity. This clinical shift has prompted warnings from surgical societies that many eligible patients may be completely bypassing surgical options in favor of pharmaceutical management without fully exploring long-term compliance, financial sustainability, or the high rates of metabolic relapse that can occur when drug treatments are paused.
To visualize the shift, the chart below tracks the divergence between the two treatment paths — a steep decline in bariatric surgery volume against a sharp climb in GLP-1 prescriptions from 2022 to 2024.
Chart: U.S. obesity rates and the surge in GLP-1 prescriptions, 2022-2024.
PUT IT IN PERSPECTIVE
Consider “Sarah,” a clinical composite character synthesized from data published in recent medical trials, including the Epic Cosmos database and the BARI-OPTIMIZE trial.
Like thousands of real Americans today, Sarah’s multi-layered journey began with a year of intensive behavioral therapy to address chronic emotional triggers, which yielded a minor 5% reduction in body weight due to metabolic adaptation.
She then turned to bariatric surgery, undergoing a laparoscopic sleeve gastrectomy that successfully altered her natural gut hormones, causing her Type 2 diabetes to go into remission and helping her lose 28% of her body weight. However, four years post-op, Sarah experienced the common “metabolic fade” where her “natural satiety hormones plateaued,” sparking intense food noise and a 35-pound weight regain.
To reverse this physiological relapse, her care team prescribed a modern, once-weekly GLP-1 receptor agonist alongside a return to cognitive counseling, allowing her to safely shed an additional 11% of her body weight and stabilize her health. By blending all three phases of obesity care into a single timeline, Sarah’s story perfectly highlights the modern reality of obesity medicine: metabolic surgery is rarely a permanent, one-and-done cure but rather a powerful foundation that often requires secondary medications and ongoing psychological support to manage a lifelong, chronic condition.
THE DRAWBACKS
While these advanced metabolic treatments offer unprecedented success rates, medical experts emphasize that each clinical avenue carries distinct physiological trade-offs and side effects.
For patients utilizing modern GLP-1s, Dr. Stanford explained that clinical trials show gastrointestinal distress is the primary hurdle, with a vast majority of patients experiencing transient nausea, vomiting, diarrhea, or constipation, particularly during the initial titration and dose-escalation phases. Beyond these manageable digestive disruptions, the FDA and independent researchers warn of more severe, though rare, systemic complications, including acute pancreatitis, gallbladder disease, and a documented loss of lean muscle mass alongside adipose tissue.
Additionally, real-world use shows a significant long-term compliance challenge. Since obesity is a chronic, relapsing disease, stopping GLP-1 therapy routinely causes a rapid rebound of “food noise” and a subsequent return to pre-treatment weight.
Older generations of anti-obesity drugs present different safety profiles; medications like orlistat cause severe gastrointestinal distress directly linked to unabsorbed fat passing through the digestive tract, while stimulant-based legacy agents carry heightened risks for cardiovascular strain, neuropsychiatric shifts, and cognitive impairment. Ultimately, even the most durable intervention, metabolic and bariatric surgery, is not without ongoing consequences, including acute operative risks, potential surgical failures such as internal hernias, and a permanent anatomical restructuring that requires lifelong clinical monitoring to prevent severe nutritional and vitamin deficiencies.
GLP-1 LITIGATION
As GLP-1 medications continue to dominate the weight-loss industry, a concurrent wave of high-stakes product liability litigation has emerged, targeting major pharmaceutical manufacturers such as Novo Nordisk and Eli Lilly.
National complex litigation firms, such as Bursor & Fisher, P.A., are actively filing lawsuits on behalf of patients who suffered severe, life-threatening gastrointestinal injuries allegedly after taking popular blockbusters like Ozempic, Wegovy, Mounjaro and Zepbound. The core of these legal actions does not center on minor, expected side effects like temporary nausea, but focuses on catastrophic physical complications that caused emergency hospitalization.
Gastroparesis (severe stomach paralysis), a condition where the stomach muscles completely fail to push food into the small intestine, was the leading claim. The condition can cause chronic malnutrition, dehydration and dangerous blockages. Plaintiffs are seeking compensation for severe intestinal and bowel obstructions (ileus)—blockages that can cut off blood flow, cause tissue death, or cause fatal abdominal infections like peritonitis if left untreated.
The primary legal argument driving these lawsuits is a “failure to warn” claim regarding the true severity and permanency of these rare conditions.
While the manufacturers’ product inserts acknowledge routine digestive disruptions, plaintiffs argue that the corporate warning labels failed to adequately disclose the risk of developing irreversible organ paralysis or obstructions so severe that patients might require permanent colostomy or ileostomy bags. Attorneys litigating these cases assert that had consumers and prescribing physicians been explicitly warned about the risk of permanent gastrointestinal destruction, many would have never chosen to use the medications.
As more everyday users come forward with allegations of severe complications from long-term GLP-1 use, these legal filings represent nationwide legal action attempting to hold pharmaceutical giants financially accountable for the alleged lasting physical hardships and medical costs claimed by plaintiffs.
BUT AT WHAT COST?
The extreme financial cost of GLP-1s has made them the center of an intense battle over healthcare affordability and insurance coverage. Without insurance, the baseline retail “list price” for brand-name anti-obesity blockbusters like Wegovy and Zepbound generally ranges from $900 to $1,400 per month, according to national market analyses by Definitive Healthcare and the National Conference of State Legislatures (NCSL). The use of programs like GoodRX can significantly reduce costs as low as $199 per month, but still totaling nearly $2,400 annually.
Because obesity medicine requires continuous, long-term adherence to maintain results, these steep prices have forced commercial insurers and major employers to aggressively restrict or outright drop coverage to avoid skyrocketing premium hikes. Data tracked by GoodRx and the Employee Benefit Research Institute reveal that commercial exclusions spiked dramatically. For instance, the number of Americans without commercial insurance coverage for Wegovy jumped by 42% over one year, forcing more than a quarter of covered GLP-1 users to pay entirely out of pocket.
The public sector is experiencing a similarly fragmented coverage landscape. Historically barred by federal statute from covering weight-loss medications under Medicare Part D, the Centers for Medicare & Medicaid Services (CMS) launched a major policy shift with the “Medicare GLP-1 Bridge” demonstration program, allowing eligible beneficiaries with severe body mass index (BMI) thresholds and accompanying health risks to access specific formulations for a fixed $50 monthly copayment. Conversely, state-level coverage remains heavily restricted: tracking by the Kaiser Family Foundation (KFF) and the NCSL shows that as of mid-2026, only 13 state Medicaid programs provide fee-for-service coverage of GLP-1s explicitly for obesity treatment, leaving the vast majority of lower-income patients entirely cut off from affordable access.
THE FUTURE OF MEDICAL WEIGHT LOSS
The future of medical weight loss is shifting toward multi-hormone targeting and easier oral delivery methods that rival the efficacy of bariatric surgery. The industry is rapidly moving beyond single-hormone mimics like Ozempic, transitioning toward “triple agonist” therapies.
According to landmark Phase 3 clinical data published by Eli Lilly in mid-2026 for its investigational drug retatrutide, targeting three metabolic pathways simultaneously (GLP-1, GIP, and glucagon) allowed participants to achieve an unprecedented average weight loss of 28.3% over 80 weeks, while significantly reversing secondary obesity complications like knee osteoarthritis pain and obstructive sleep apnea.
Additionally, pharmaceutical pipelines are solving the logistical bottleneck of weekly injections by introducing highly effective, needle-free alternatives. A market outlook report by WTW and a pipeline update from Prime Therapeutics highlight that the FDA’s April 2026 approval of Foundayo (orforglipron), the first non-peptide, small-molecule oral GLP-1 tablet, marked a critical milestone. Because it lacks strict food and water dosing restrictions and bypasses the expensive refrigeration requirements of traditional injectables, it offers a drastically more scalable, mass-producible solution.
Looking ahead toward late 2026 and 2027, combination treatments like Novo Nordisk’s CagriSema (which pairs semaglutide with the fullness hormone amylin) and Amgen’s long-acting MariTide (aiming for monthly or quarterly dosing intervals) are poised to completely redefine long-term maintenance, establishing a multi-system therapeutic platform that targets whole-body health rather than just cosmetic weight reduction.
Ultimately, the rapidly evolving landscape of weight management proves that obesity can no longer be viewed as a simple failure of personal willpower, but rather as a complex, chronic biological disease. As the medical community balances the immediate relief of breakthrough pharmaceuticals against the realities of clinical side effects, insurance battles, and ongoing product litigation, one truth remains clear: there is no one-size-fits-all cure. Whether through lifestyle modification, advanced surgical restructuring, or the next generation of multi-hormone smart drugs, the future of healthcare lies in a sustainable, multi-tiered approach that prioritizes long-term whole-body health over quick-fix solutions.
